

Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.

Céline Dartois, Karl Brendel, Emmanuelle Comets, Céline Laffont, Christian Laveille, Brigitte Tranchand, France Mentré, Annabelle Lemenuel-Diot, Pascal Girard

▶ To cite this version:

Céline Dartois, Karl Brendel, Emmanuelle Comets, Céline Laffont, Christian Laveille, et al.. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. British Journal of Clinical Pharmacology, Wiley, 2007, 64 (5), pp.603-12. <10.1111/j.1365-2125.2007.02975.x>. <inserm-00159122>

HAL Id: inserm-00159122 http://www.hal.inserm.fr/inserm-00159122

Submitted on 14 Sep 2009

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Data Abstraction Form for population PK/PD publications

GENERAL CHARACTERISTICS

Brendel K.^{1*}, Dartois C.^{2*},

Comets E.¹, Lemenuel-Diot A.³, Laffont C.M.³, Laveille C.⁴,

Girard P.², Mentré F.¹

¹INSERM U738, Paris, France

²EA3738, Lyon, France

³SERVIER, Courbevoie, France

⁴EXPRIMO NV, Lumnen, Belgium

^{*} the two first authors contributed equally to this Data Abstraction Form

Table of contents

	ARTICLE IDENTIFICATION	3
	Date of publication (year)	3
	Title	3
	First author	3
	Journal	3
I.	CONTEXT OF THE ANALYSIS	4
	Team performing the analysis	4
	Drug(s) administered	4
II.	CLINICAL STUDY(ies)	5
	Phase(s) of clinical development	5
	Main objective(s) of the clinical study(ies)	5
	Target population of the clinical study(ies)	5
	Administration route(s)	5
	Dose	6
	Number of center(s) involved	6
	Duration of the clinical study(ies)	6
	Duration of the treatment(s)	6
	Experimental design	6

ARTICLE IDENTIFICATION

DATE OF PUBLICATION (YEAR)
TITLE
•••••
FIRST AUTHOR
Journal
Anesthesiology
Antimicrobial Agents and Chemotherapy
British Journal of Clinical Pharmacology
Cancer Chemotherapy and Pharmacology
Clinical Pharmacokinetics
Clinical Pharmacology and Therapeutics
Clinical Therapeutics
European Journal of Cancer
European Journal of Clinical Pharmacology
European Journal of Drug Metabolism and Pharmacokinetics
European Journal of Pharmaceutical sciences
Journal of Acquired Immune Deficiency Syndromes
Journal of Clinical Oncology
Journal of Pharmaceutical Sciences
Journal of Pharmacokinetics and Pharmacodynamics
Journal of Pharmacy and Pharmacology
Therapeutic Drug Monitoring
Pharmacotherapy
Other:

I. CONTEXT OF THE ANALYSIS				
Team performing the analysis				
Industry (R & D)	☐ Not reported			
Academic/Hospital				
Drug Agency				
Drug(s) administered ¹				
Therapeutic class(es) studied in thi	s analysis ²			
Antidotes	Antimicrobials			
Antiparasitics	Cardiovascular-renal			
Central nervous system	Contrast media / Radiopharmaceuticals			
Gastrointestinals Hematologics				
Hormones / Hormonal mechanisms	☐ Immunologics			
Metabolics / Nutrients	☐ Neurologics			
Oncolytics	Ophtalmics			
Otics	Pain relief			
Respiratory tract	Skin / Mucous membranes			
Other				

¹ International Nonproprietary Names (=DCI) (if not published, company identification number)

² Major classes of FDA National Drug Code Directory (http://www.fda.gov/cder/ndc/tbldclas.txt)

II. CLINICAL STUDY(ie	es)	
Phase(s) of clinical development		
Combined studies	Not reported	
Phase I	Phase III	
Phase II	Observational studies	S
Main objective(s) of the clinical s	tudy(ies)	
☐ PK ☐ PD		☐ Not reported
☐ Dose finding ☐ Dru	ig interaction	
☐ Efficacy ☐ TD	M	
☐ Toxicity ☐ Oth	ier:	
Target population of the clinical	study(ies)	
Total number of Subjects:		
Adults Paediatrics	Elderly	Not reported
Healthy volunteers Patients	Special population	Not reported
Administration route(s)		
☐ PO ☐ Nasal		Not reported
☐ IV (bolus) ☐ IV (Infusion)	SC	Intraperitoneal
☐ IM ☐ Transdermal	Rectal	Ophtalmic
Other:		

Dose				
Single dose				Not reported
Multiple cycles				
Number of center(s) involved				
Monocentric				☐ Not reported
Multicentric				
Duration of the clinical study(ie	es)			
days	Unclear			Not reported
Duration of the treatment(s)				
days	Unclear			Not reported
Experimental design				
Number of Arms:				☐ Not reported
Cohort study				
if number of arms >1:				
Parallel group				Not reported
Cross-over study				
Dose escalation (titre	ation) Ye	es]	No	Not reported
Randomization	Yo	es]	No	Not reported
Is there a comparator?				
None				Not reported
Placebo				
Reference treatm	nent(s)			
Other, define:				
Are the design optimised with respect to the sampling times				
	Ye	es]	No	